Taser research in pigs not helpful.

hese failed procedures, an additional analysis was stated a priori in etail in the statistical analysis plan prior to unblinding in which he lowest (i.e., worst) CFR from the prior ESPRIT (Enhanced uppression of the Platelet IIb/IIIa Receptor with Integrilin herapy) substudy (0.55) was imputed to those patients with a ailed procedure. When patients with a failed procedure were ncluded in the analysis, no difference was seen between bivalirudin nd eptifibatide in the primary end point (median of 1.43 for ivalirudin vs. 1.33 for pooled eptifibatide arms, p 0.13). To omply with the requests of the reviewers, however, the analysis in he published report included only patients with a successful PCI nd does not account for patients with a failed procedure. Given the potential for clopidogrel pretreatment to confound he efficacy outcomes in the trial, randomization in the trial was tratified by clopidogrel pretreatment, and it was prespecified that he key analyses would be adjusted for clopidogrel pretreatment. In prespecified analysis, there was a significant interaction term etween clopidogrel pretreatment and the randomization arm with espect to the end point of death or myocardial infarction (MI) p 0.031 for interaction between clopidogrel pretreatment and andomization arm). Among patients treated with clopidogrel for 6 h before angiography, the risk of death/MI was significantly ower among patients treated with eptifibatide compared with ivalirudin (5.0% vs. 10.3%, n 548, p 0.022). In the smaller ohort of 309 patients treated with clopidogrel for 6 h, no ignificant difference existed in the incidence of death/MI between ptifibatide and bivalirudin (9.5% vs. 6.1%, p 0.31). Among roponin-positive patients treated for 6 h with clopidogrel, the isk of death/MI was significantly lower among patients treated ith eptifibatide (4.1%, n 197 vs. 13.2%, n 106, p 0.003).